IFNK and Schwartz-Jampel syndrome: Given the pivotal role of type 1 IFN in SjS and the urgent need for treatments (23), we investigated in a preclinical study using the MRL/MpJ-Faslpr/lpr (MRL/lpr) model, a well-recognized mouse model of systemic autoimmunity with SjS-like features (24), the potential benefits of the murine surrogate of the human IFN-K vaccine.